IL288051A - Treatment of systolic dysfunction and reduced ejection fraction heart failure with the compound (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)1-sulfonyl))-n- (isoxazol-3-yl)piperidine-1-carboxamide - Google Patents

Treatment of systolic dysfunction and reduced ejection fraction heart failure with the compound (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)1-sulfonyl))-n- (isoxazol-3-yl)piperidine-1-carboxamide

Info

Publication number
IL288051A
IL288051A IL288051A IL28805121A IL288051A IL 288051 A IL288051 A IL 288051A IL 288051 A IL288051 A IL 288051A IL 28805121 A IL28805121 A IL 28805121A IL 288051 A IL288051 A IL 288051A
Authority
IL
Israel
Prior art keywords
isoxazol
fluoroethyl
difluoromethyl
pyrazol
carboxamide
Prior art date
Application number
IL288051A
Other languages
English (en)
Hebrew (he)
Inventor
Inc Myokardia
Jean-Francois Tamby
Chun Yang
Timothy Carlson
Original Assignee
Inc Myokardia
Tamby Jean Francois
Chun Yang
Timothy Carlson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inc Myokardia, Tamby Jean Francois, Chun Yang, Timothy Carlson filed Critical Inc Myokardia
Publication of IL288051A publication Critical patent/IL288051A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL288051A 2019-05-19 2021-11-11 Treatment of systolic dysfunction and reduced ejection fraction heart failure with the compound (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)1-sulfonyl))-n- (isoxazol-3-yl)piperidine-1-carboxamide IL288051A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849936P 2019-05-19 2019-05-19
US201962852739P 2019-05-24 2019-05-24
PCT/US2020/033438 WO2020236736A1 (en) 2019-05-19 2020-05-18 Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Publications (1)

Publication Number Publication Date
IL288051A true IL288051A (en) 2022-01-01

Family

ID=70978663

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288051A IL288051A (en) 2019-05-19 2021-11-11 Treatment of systolic dysfunction and reduced ejection fraction heart failure with the compound (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)1-sulfonyl))-n- (isoxazol-3-yl)piperidine-1-carboxamide

Country Status (16)

Country Link
US (2) US20220265629A1 (enExample)
EP (1) EP3972597A1 (enExample)
JP (2) JP2022535195A (enExample)
KR (1) KR20220009440A (enExample)
CN (1) CN114173782A (enExample)
AU (2) AU2020279710A1 (enExample)
BR (1) BR112021023074A2 (enExample)
CA (1) CA3138080A1 (enExample)
CL (1) CL2021003045A1 (enExample)
CO (1) CO2021015505A2 (enExample)
IL (1) IL288051A (enExample)
MX (2) MX2021014109A (enExample)
PE (1) PE20220426A1 (enExample)
SG (1) SG11202112723PA (enExample)
TW (2) TW202541801A (enExample)
WO (1) WO2020236736A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020315605A1 (en) 2019-07-16 2022-03-03 MyoKardia, Inc. Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide
KR102752382B1 (ko) * 2019-09-20 2025-01-09 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 안지오텐신 ii 수용체 길항제 대사물질 및 nep 억제제의 복합체의 심부전 치료에서의 용도
IL298885A (en) * 2020-06-15 2023-02-01 Myokardia Inc Treatment of atrial function
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure
US20250025460A1 (en) * 2021-12-02 2025-01-23 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
JP2014088342A (ja) * 2012-10-30 2014-05-15 Kowa Company Ltd ベンゾオキサジアゾール誘導体を有効成分とするｍｋ２阻害剤
PH12021553074A1 (en) * 2015-01-22 2023-03-06 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
LT3645002T (lt) * 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
WO2019006325A1 (en) * 2017-06-30 2019-01-03 Equalaire Systems, Inc. VENT CAP OF HUB CAP

Also Published As

Publication number Publication date
CL2021003045A1 (es) 2022-07-08
US20220265629A1 (en) 2022-08-25
MX2021014109A (es) 2021-12-10
WO2020236736A1 (en) 2020-11-26
TW202110449A (zh) 2021-03-16
CA3138080A1 (en) 2020-11-26
MX2025003918A (es) 2025-05-02
BR112021023074A2 (pt) 2022-03-29
EP3972597A1 (en) 2022-03-30
SG11202112723PA (en) 2021-12-30
AU2025263744A1 (en) 2025-11-20
PE20220426A1 (es) 2022-03-29
TW202541801A (zh) 2025-11-01
AU2020279710A1 (en) 2021-12-23
JP2025106475A (ja) 2025-07-15
US20250241903A1 (en) 2025-07-31
CN114173782A (zh) 2022-03-11
KR20220009440A (ko) 2022-01-24
TWI874399B (zh) 2025-03-01
CO2021015505A2 (es) 2021-12-10
JP2022535195A (ja) 2022-08-05

Similar Documents

Publication Publication Date Title
MX2025003918A (es) Tratamiento de la disfuncion sistolica
IL272032B2 (en) Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and
IL289817A (en) Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine -1-carboxamide
EP4424320A3 (en) Acylated glp-1/glp-2 dual agonists
ZA202000145B (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
WO2014188279A3 (en) Apparatus for delivering devices for reducing left atrial pressure
JP2013531028A5 (enExample)
IL285675A (en) Crystalline form of 1-(1-oxo-2,1-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
ZA202106236B (en) N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use
WO2017164576A8 (en) Novel crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine salt
LT4161929T (lt) 1-(5-(2-cianopiridin-4-il)oksazol-2-karbonil)-4- metilheksahidropirolo[3,4-b]pirolo-5(1h)-karbonitrilas kaip usp30 inhibitorius, skirtas mitochondrijų disfunkcijos, vėžio ir fibrozės gydymui
HK40068675A (en) Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
PT4079293T (pt) Composição farmacêutica líquida de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1hpirrol-3-il)-n-metilmetanamina
HK40072372A (en) Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
EP3233824A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
EP4041726B8 (en) Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine
EP3233079A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
IL281276A (en) (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of using them
PH12019501165A1 (en) Drug for treating cocaine addiction or preventing recurrence of same
HK40073223A (en) Treatment of glycogen storage disease (gsd)
HK40065506A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
HK40050762A (en) 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use
HK40117732A (en) Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2
CA3301522A1 (en) Compound azd5462 for use in the treatment of heart failure
HK40071100A (zh) 曲马多和塞来昔布的共晶体用於治疗疼痛同时降低曲马多的滥用倾向的用途